BeyondSpring Inc. (NASDAQ:BYSI) is set to announce its earnings results before the market opens on Thursday, November 9th. Analysts expect the company to announce earnings of ($0.69) per share for the quarter.

ILLEGAL ACTIVITY NOTICE: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at

Several brokerages recently issued reports on BYSI. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of BeyondSpring in a research report on Monday, August 21st. Rodman & Renshaw upped their price objective on shares of BeyondSpring from $43.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, July 14th. Zacks Investment Research upgraded shares of BeyondSpring from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Finally, Maxim Group started coverage on shares of BeyondSpring in a report on Tuesday, August 22nd. They issued a “buy” rating and a $52.00 price objective on the stock.

About BeyondSpring

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with's FREE daily email newsletter.